Credit score: Pixabay/CC0 Public Area
Cedars-Sinai physician-scientists joined friends from world wide on the Alzheimer’s Affiliation Worldwide Convention in July. The scientific displays on the convention included information from medical trials of potential therapies for the neurodegenerative illness.
Nonetheless, greater than 90% of Alzheimer’s illness trials don’t yield the hoped-for outcome, mentioned Mitzi Gonzales, Ph.D., director of Translational Analysis within the Jona Goldrich Heart for Alzheimer’s and Reminiscence Issues. There’s nonetheless one thing to be taught from every research, Gonzales mentioned.
“Even trials that aren’t considered successful are incredibly important in shaping our scientific knowledge,” Gonzales mentioned. “Trials that show us that one pathway isn’t working can push us in new directions.”
That was the case with the just lately printed outcomes of a trial that Gonzales led testing a drug referred to as rapamycin. In preclinical research, rapamycin was related to elevated longevity and discount in lots of age-related signs and circumstances.
The paper is printed within the journal Communications Medication.
“Data from preclinical studies showed rapamycin reduced the buildup of amyloid beta and tau proteins in the brain, which we know are associated with Alzheimer’s disease,” Gonzales mentioned. “We were hoping to see similar results in humans.”
As a substitute, ranges of amyloid and tau elevated, Gonzales mentioned.
“That result has raised its own scientific questions and led to some other avenues of research,” Gonzales mentioned. “So it has been helpful for pushing us in new directions, including looking at whether it might be more effective in earlier-stage disease.”
Samples—similar to blood and cerebrospinal fluid—taken throughout unsuccessful medical trials can even result in breakthroughs down the street, mentioned Sarah Kremen, MD, director of the Neurobehavior Program.
“The pivotal A4 study tested a drug called solanezumab in cognitively normal people with elevated amyloid,” Kremen mentioned. “The drug did not improve cognition or remove amyloid from the brain, but it was the first time that we’d ever studied anybody who was asymptomatic but at risk. It was a really big deal.”
Research accomplished with samples from that trial contributed to a bigger physique of labor displaying {that a} biomarker referred to as pTau217 will be an early indicator of Alzheimer’s illness. And that marker is used within the first Meals and Drug Administration-approved blood check for the buildup of amyloid plaques within the mind, Kremen mentioned.
Gonzales and Kremen famous the numerous causes Alzheimer’s illness has proved so difficult, together with its a number of doubtless causes, the truth that these components are current for a few years earlier than the illness is detectable, and the complexity of the mind itself.
“The brain is not as well understood as other organs and the processes underlying neurodegenerative disease are complex,” Kremen mentioned. “It will take time—and many more clinical trials—to unravel all the different mechanisms behind Alzheimer’s disease.”
Extra data:
Mitzi M. Gonzales et al, Rapamycin remedy for Alzheimer’s illness and associated dementias: a pilot section 1 medical trial, Communications Medication (2025). DOI: 10.1038/s43856-025-00904-9
Offered by
Cedars-Sinai Medical Heart
Quotation:
Alzheimer’s illness: The complexities of medical trials (2025, August 11)
retrieved 12 August 2025
from https://medicalxpress.com/information/2025-08-alzheimer-disease-complexities-clinical-trials.html
This doc is topic to copyright. Aside from any truthful dealing for the aim of personal research or analysis, no
half could also be reproduced with out the written permission. The content material is offered for data functions solely.
